Turn Therapeutics (NASDAQ:TTRX) Upgraded at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at WBB Securities from a “sell” rating to a “hold” rating in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a $10.00 price objective on the stock. WBB Securities‘s price target would indicate a potential downside of 1.77% from the stock’s current price.

A number of other brokerages have also recently issued reports on TTRX. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Wall Street Zen downgraded Turn Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 18th. Finally, Zacks Research upgraded Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Price Performance

TTRX opened at $10.18 on Friday. Turn Therapeutics has a one year low of $2.57 and a one year high of $16.45. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The company’s 50 day simple moving average is $11.63 and its 200-day simple moving average is $8.13. The stock has a market capitalization of $310.80 million and a P/E ratio of -35.10.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Sell-side analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Ieq Capital LLC acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at $1,660,000. Bridgewater Advisors Inc. acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at $242,000. DDFG Inc grew its holdings in shares of Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after buying an additional 18,246 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Turn Therapeutics in the 3rd quarter valued at $40,000. Finally, SteelPeak Wealth LLC grew its holdings in shares of Turn Therapeutics by 0.7% in the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after buying an additional 1,819 shares during the period.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.